Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Cross-neutralization of cutaneous and mucosal Papillomavirus types with anti-sera to the amino terminus of L2

11 May 2005

Abstract excerpt

No abstract is available from the source.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cervical Cancer and HPV Research
Share to Genital Health and Disease
Share to Poxvirus research and outbreaks

Source

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Identifiers

PMID: 15885736
DOI: 10.1016/j.virol.2005.04.011

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Cross-neutralization of cutaneous and mucosal Papillomavirus types with anti-sera to the amino terminus of L2PMID 15885736Read ↗

The N-terminal region of the human papillomavirus L2 protein contains overlapping binding sites for neutralizing, cross-neutralizing and non-neutralizing antibodiesSemantic proximity Read ↗

L2 epitope presenting virus-like particles as broad- spectrum vaccine candidates targeting genus beta human papillomavirusesSemantic proximity Read ↗

Progress in L2-Based Prophylactic Vaccine Development for Protection against Diverse Human Papillomavirus Genotypes and Associated DiseasesSemantic proximity Read ↗

Immunization with a consensus epitope from human papillomavirus L2 induces antibodies that are broadly neutralizingSemantic proximity Read ↗

Natural variants in the major neutralizing epitope of human papillomavirus minor capsid protein L2.Semantic proximity Read ↗

VLPs Displaying a Single L2 Epitope Induce Broadly Cross-Neutralizing Antibodies against Human PapillomavirusSemantic proximity Read ↗

A Pan-HPV Vaccine Based on Bacteriophage PP7 VLPs Displaying Broadly Cross-Neutralizing Epitopes from the HPV Minor Capsid Protein, L2Semantic proximity Read ↗

Minor Capsid Protein of Human Genital Papillomaviruses Contains Subdominant, Cross-Neutralizing EpitopesSemantic proximity Read ↗

Chimeric L2-Based Virus-Like Particle (VLP) Vaccines Targeting Cutaneous Human Papillomaviruses (HPV)Semantic proximity Read ↗

Substitution of Human Papillomavirus Type 16 L2 Neutralizing Epitopes Into L1 Surface Loops: The Effect on Virus-Like Particle Assembly and ImmunogenicitySemantic proximity Read ↗

Identification of Broad-Genotype HPV L2 Neutralization Site for Pan-HPV Vaccine Development by a Cross-Neutralizing Antibody.Semantic proximity Read ↗

A Human Papillomavirus (HPV) <i>In Vitro</i> Neutralization Assay That Recapitulates the <i>In Vitro</i> Process of Infection Provides a Sensitive Measure of HPV L2 Infection-Inhibiting AntibodiesSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.